Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $99.1111.Get Structure Therapeutics alerts:Can Roche Challenge Lilly and Novo in the Weight Loss Market?A number of equities research analysts recently weighed in on GPCR shares. HC Wainwright raised their price target on Structure Therapeutics from $60.00 to $90.00 and gave the company a "buy" rating in a report on Friday, December 19th. Lifesci Capital upgraded shares of Structure Therapeutics to a "strong-buy" rating in a report on Monday, September 8th. Citigroup restated an "outperform" rating on shares of Structure Therapeutics in a report on Friday, December 12th. Piper Sandler reissued an "overweight" rating on shares of Structure Therapeutics in a report on Tuesday, October 28th. Finally, Zacks Research lowered Structure Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Friday, October 17th.Check Out Our Latest Analysis on Structure TherapeuticsStructure Therapeutics Trading Down 1.9%Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug EmergesGPCR stock opened at $69.95 on Thursday. The business's 50 day moving average is $41.18 and its 200-day moving average is $28.21. Structure Therapeutics has a 1-year low of $13.22 and a 1-year high of $94.90. The firm has a market cap of $4.24 billion, a P/E ratio of -57.33 and a beta of -1.64. Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). Sell-side analysts forecast that Structure Therapeutics will post -0.82 EPS for the current year. Institutional Trading of Structure TherapeuticsAltimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. increased its position in shares of Structure Therapeutics by 6.1% in the first quarter. Invesco Ltd. now owns 394,386 shares of the company's stock valued at $6,827,000 after acquiring an additional 22,619 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Structure Therapeutics during the first quarter worth approximately $249,000. Jump Financial LLC bought a new stake in Structure Therapeutics in the 1st quarter valued at $532,000. Trexquant Investment LP grew its stake in shares of Structure Therapeutics by 127.6% in the first quarter. Trexquant Investment LP now owns 120,340 shares of the company's stock valued at $2,083,000 after acquiring an additional 67,464 shares in the last quarter. Finally, DAFNA Capital Management LLC grew its position in shares of Structure Therapeutics by 66.2% during the 1st quarter. DAFNA Capital Management LLC now owns 59,000 shares of the company's stock worth $1,021,000 after purchasing an additional 23,500 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds. Structure Therapeutics Company Profile (Get Free Report)Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders. The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.Read MoreFive stocks we like better than Structure TherapeuticsDo not delete, read immediatelyINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffCan Any Expenses Be Deducted From Capital Gains Tax?Buffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyForget AI, This Will Be the Next Big Tech BreakthroughThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Structure Therapeutics Right Now?Before you consider Structure Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.While Structure Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here